Open-label, single-arm, single-center phase 1b/2 clinical study of fruquintinib combined with trastuzumab and XELOX in the first-line treatment of advanced HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Huifang Lv, Yunduan He, Caiyun Nie, Beibei Chen, Weifeng Xu, Jianzheng Wang, Jing Zhao, Xiaobing Chen
Institutions: Zhengzhou University, Henan Cancer Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410815823